Tivic Health Systems, Inc. (TIVC) Stock Profile — Insider Trades & Financials

Revenue$0

Net Income-$2.8M

EPS$-4.64

Market Cap$3.0M

Price Performance

Historical data including institutional events

Loading price data...

Company Profile

Michael Handley

CEO & Executive Director

Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The companyâs pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.

Founded: 2016
Employees: 7
Headquarters: Fremont, California, United States
Website

⚡

Core Efficiency

ROE?

-85.99%

ROA?

-9.01%

D/E Ratio?

2.25

📊

Profitability Ratios

Current Ratio?

20.13

Loading comparison...

Earnings Calendar

Filing history and next expected filing date

Next Expected Filing

Sep 12, 2026 (in 156 days)

Annual Report (10-K) — Based on filing pattern

Sep 12, 2026

Predicted10-K

Mar 30, 2026

10-KQ4 202513d after period end

Mar 30, 2026

10-KFY 202589d after period end

Nov 14, 2025

10-QQ3 20252d after period end

Aug 14, 2025

10-QQ2 20252d after period end

May 15, 2025

10-QQ1 20253d after period end

Mar 21, 2025

10-KQ4 20244d after period end

Mar 21, 2025

10-KFY 202480d after period end

Nov 14, 2024

10-QQ3 20242d after period end

Loading company sections...

Tivic Health Systems, Inc.

Price Performance

Company Profile

Core Efficiency

Profitability Ratios

Earnings Calendar

Core Efficiency

Profitability Ratios

Earnings Calendar

Data Freshness